{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:42:05Z","timestamp":1771674125970,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T00:00:00Z","timestamp":1430524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T00:00:00Z","timestamp":1430524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10637-015-0242-6","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T06:40:54Z","timestamp":1430462454000},"page":"870-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Phase 1 dose escalation trial of ilorasertib, a dual Aurora\/VEGF receptor kinase inhibitor, in patients with hematologic malignancies"],"prefix":"10.1007","volume":"33","author":[{"given":"Guillermo","family":"Garcia-Manero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wijith","family":"Munasinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Roberts-Rapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"McKee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin L.","family":"Ricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,2]]},"reference":[{"issue":"17","key":"242_CR1","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17):2943\u20132964","journal-title":"Blood"},{"issue":"4","key":"242_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1053\/j.seminhematol.2013.09.006","volume":"50","author":"E Jabbour","year":"2013","unstructured":"Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian H (2013) Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 50(4):271\u2013283","journal-title":"Semin Hematol"},{"issue":"1","key":"242_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-8722-6-54","volume":"6","author":"K Sweet","year":"2013","unstructured":"Sweet K, Zhang L, Pinilla-Ibarz J (2013) Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol 6(1):54","journal-title":"J Hematol Oncol"},{"key":"242_CR4","doi-asserted-by":"crossref","unstructured":"Wiestner A (2012) Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (88\u201396, 2012","DOI":"10.1182\/asheducation.V2012.1.88.3801172"},{"issue":"5","key":"242_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40291-012-0006-3","volume":"16","author":"R Tibes","year":"2012","unstructured":"Tibes R, Bogenberger JM, Benson KL, Mesa RA (2012) Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. Mol Diagn Ther 16(5):269\u2013283","journal-title":"Mol Diagn Ther"},{"issue":"11","key":"242_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nrc925","volume":"2","author":"S Rafii","year":"2002","unstructured":"Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2(11):826\u2013835","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"242_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669\u2013676","journal-title":"Nat Med"},{"issue":"7070","key":"242_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nature04480","volume":"438","author":"K Alitalo","year":"2005","unstructured":"Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438(7070):946\u2013953","journal-title":"Nature"},{"issue":"14","key":"242_CR9","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1038\/sj.emboj.7600289","volume":"23","author":"J Dong","year":"2004","unstructured":"Dong J, Grunstein J, Tejada M, Peale F, Frantz G, Liang WC, Bai W, Yu L, Kowalski J, Liang X, Fuh G, Gerber HP, Ferrara N (2004) VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23(14):2800\u20132810","journal-title":"EMBO J"},{"issue":"2","key":"242_CR10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/0008-5472.CAN-05-4005","volume":"66","author":"CE Lewis","year":"2006","unstructured":"Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605\u2013612","journal-title":"Cancer Res"},{"key":"242_CR11","doi-asserted-by":"crossref","unstructured":"Levis M (2013) FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program (220\u2013226, 2013","DOI":"10.1182\/asheducation-2013.1.220"},{"issue":"9","key":"242_CR12","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/sj.leu.2403099","volume":"17","author":"M Levis","year":"2003","unstructured":"Levis M, Small D (2003) FLT3: ITDoes matter in leukemia. Leukemia 17(9):1738\u20131752","journal-title":"Leukemia"},{"issue":"1","key":"242_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cancergencyto.2004.09.008","volume":"159","author":"J Zhu","year":"2005","unstructured":"Zhu J, Abbruzzese JL, Izzo J, Hittelman WN, Li D (2005) AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 159(1):10\u201317","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"242_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00428-006-0360-9","volume":"450","author":"G Qi","year":"2007","unstructured":"Qi G, Ogawa I, Kudo Y, Miyauchi M, Siriwardena BS, Shimamoto F, Tatsuka M, Takata T (2007) Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 450(3):297\u2013302","journal-title":"Virchows Arch"},{"issue":"11","key":"242_CR15","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1535-7163.MCT-06-0301","volume":"5","author":"B Vischioni","year":"2006","unstructured":"Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G (2006) Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 5(11):2905\u20132913","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"242_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","volume":"5","author":"J Fu","year":"2007","unstructured":"Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5(1):1\u201310","journal-title":"Mol Cancer Res"},{"issue":"6","key":"242_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2174\/187152007784111278","volume":"7","author":"FM Johnson","year":"2007","unstructured":"Johnson FM, Gallick GE (2007) SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651\u2013659","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"242_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/10428190701713689","volume":"49","author":"S Li","year":"2008","unstructured":"Li S (2008) Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 49(1):19\u201326","journal-title":"Leuk Lymphoma"},{"key":"242_CR19","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Tibes R, Chiu YL, Xiong H, Qin Q, Ansell P, Albert DH, C\/ T, Oliver B, Sajwani K, McKee MD, Ricker J, Khoury HJ (2012) Phase 1 study of ABT-348, a dual Aurora\/VEGF-receptor kinase inhibitor, in patients with advanced hematologic malignancies. Abstract 2617. Blood 120","DOI":"10.1182\/blood.V120.21.2617.2617"},{"issue":"3","key":"242_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1124\/jpet.112.197087","volume":"343","author":"KB Glaser","year":"2012","unstructured":"Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH (2012) Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor\/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther 343(3):617\u2013627","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"242_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00280-012-1846-6","volume":"69","author":"H Asahina","year":"2012","unstructured":"Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T (2012) An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 69(6):1477\u20131486","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"242_CR22","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642\u20134649","journal-title":"J Clin Oncol"},{"key":"242_CR23","unstructured":"National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology\u2014Chronic Myelogenous Leukemia. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"issue":"9","key":"242_CR24","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.leukres.2013.04.025","volume":"37","author":"C Graux","year":"2013","unstructured":"Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG (2013) A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. Leuk Res 37(9):1100\u20131106","journal-title":"Leuk Res"},{"key":"242_CR25","doi-asserted-by":"crossref","unstructured":"Mita M, Gordon M, Rejeb N, Gianella-Borradori A, Jego V, Mita A, Sarantopoulos J, Sankhala K, Mendelson D (2013) A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol","DOI":"10.1007\/s11523-013-0288-3"},{"issue":"2","key":"242_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-010-1318-9","volume":"67","author":"AM Traynor","year":"2011","unstructured":"Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, Scott BB, Leighton AM, Watson PA, Zhao B, O'Dwyer PJ, Wilding G (2011) Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 67(2):305\u2013314","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"242_CR27","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.1158\/1078-0432.CCR-09-1445","volume":"15","author":"RB Cohen","year":"2009","unstructured":"Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, Comis S, Laffranchi B, Moll J, Burris HA (2009) A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 15(21):6694\u20136701","journal-title":"Clin Cancer Res"},{"issue":"12","key":"242_CR28","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1158\/1078-0432.CCR-06-2979","volume":"13","author":"RW Wilkinson","year":"2007","unstructured":"Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S (2007) AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 13(12):3682\u20133688","journal-title":"Clin Cancer Res"},{"issue":"6","key":"242_CR29","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","volume":"6","author":"RK Jain","year":"2009","unstructured":"Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6(6):327\u2013338","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"242_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.leukres.2012.10.017","volume":"37","author":"W Qi","year":"2013","unstructured":"Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP, Mahadevan D (2013) Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37(4):434\u2013439","journal-title":"Leuk Res"},{"issue":"1","key":"242_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","volume":"32","author":"JW Friedberg","year":"2014","unstructured":"Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH (2014) Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 32(1):44\u201350","journal-title":"J Clin Oncol"},{"issue":"1","key":"242_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2012.06.040","volume":"127","author":"UA Matulonis","year":"2012","unstructured":"Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ (2012) Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 127(1):63\u201369","journal-title":"Gynecol Oncol"},{"issue":"6","key":"242_CR33","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s10637-012-9798-6","volume":"30","author":"M Kollareddy","year":"2012","unstructured":"Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M (2012) Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 30(6):2411\u20132432","journal-title":"Invest New Drugs"},{"issue":"3","key":"242_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1517\/13543784.2012.652303","volume":"21","author":"HJ Meulenbeld","year":"2012","unstructured":"Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ (2012) Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs 21(3):383\u2013393","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-015-0242-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0242-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-015-0242-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:43:27Z","timestamp":1678509807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-015-0242-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,2]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s10637-015-0242-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,2]]},"assertion":[{"value":"23 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}